Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

nnovations in patients with atrial fibrillation in the last twenty years.

The efficacy and safety of Multaq(R) 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq(R).

The ATHENA trial, which involved 4,628 patients with AF or AFL and more than 2,300 patients receiving Multaq(R) on top of standard therapy, demonstrated a 24% reduction in time to first CV hospitalization or all-cause mortality (P<0.001) compared with placebo meeting the primary endpoint.

The ANDROMEDA study, was terminated prematurely after enrolment of 627 of 1000 planned patients with congestive heart failure, in relation to excess mortality due to worsening heart failure in the dronedarone group [n=25 versus 12 (placebo), p=0.027].

The patient population enrolled in the ANDROMEDA and ATHENA studies was significantly different. The patients enrolled in ANDROMEDA had relatively severe heart failure and had been hospitalized, or referred to a specialty heart failure clinic for worsening symptoms. Patients were predominantly NYHA II and III (New York Heart Association classification) and only 25% had a history of AF/AFL at randomization. In contrast, in ATHENA, all patients had a history of AF/AFL, and 71% of patients had no heart failure, 25% were NYHA class I or II, and only 4% were class III.

The ANDROMEDA and ATHENA trials were published in the New England Journal of Medicine (NEJM) respectively in 2008 and 2009.

Important Safety Information

Multaq(R) is contraindicated in patients with NYHA Class IV heart failure or NYHA Class II-III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. In a placebo-controlled study in patients with severe heart failure requiring recent
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NJ (PRWEB) August 01, 2014 ... web portal that aims to empower patients and ... in their health care by providing easy, secure ... Portal gives patients instant, web-based access to their ... and radiology results, medications, allergies, demographic information, visit ...
(Date:8/1/2014)... procedures have grown in popularity as more and more ... toxin generally known as BOTOX use ... have emerged to perform procedures utilizing this and other ... from the Division of Plastic Surgery Presbyterian Hospital in ... University in New York have assessed the capability of ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 St. Christopher's ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , St. Christopher's Hospital ... services for children from birth through 21 years of ... several of the hospital's specialties, including autism and childhood ...
(Date:8/1/2014)... Narconon Arrowhead recently celebrated the occasion ... drug rehab center located in the small town of ... is the flagship drug rehab center in the Narconon ... for services there. Now, with such a long track ... as well as client reviews showing the effectiveness of ...
(Date:8/1/2014)... TX (PRWEB) August 01, 2014 Delta ... the Year for its outstanding commitment to St. Jude ... the hospital since 1999 and pledging to raise another ... combat childhood cancer and other deadly diseases. , ... any single partner in St. Jude history. Specifically, it ...
Breaking Medicine News(10 mins):Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 2Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 3
... that vitamin C was vital for good health and could ... ,Dr Margret Vissers, from Otago University's Free Radical Research ... vitamin C was a vital part of healthy living and ... had a cold. ,"I've found that vitamin C ...
... nerve cells in the brain and lead to depression, according to ... and Science in North Chicago. ,The team led by Daniel ... rats for 20 minutes. The older rats quickly cornered, pinned down ... ,The younger rats became fearful and acted depressed in the ...
... below seven is fast depleting, which has sent the Ministry of ... Company CSL had stopped the production of the Tet-tox vaccine in ... is just enough to last till the end of this month. ... drugs will have to be used by those who are in ...
... New research suggests that a child’s race may ... tobacco toxins associated with environmental tobacco smoke (ETS). ... asthma, who are exposed to ETS, have significantly ... counterparts. ,“African American children suffer from ...
... question of bloodshot eyes anymore. After sleepless nights, a person’s ... has been found//. ,Sleep deprivation lowers metabolic ... colleagues at Walter Reed Army Institute of Research, report in ... group of volunteers to two sleepless nights, they found that ...
... Patients can start using their mobile phones when the ban ... in the hospitals because it was believed// that its electromagnetic ... per the directive issued from the Department of Health, cell ... equipments. ,This announcement has brought in cheer ...
Cached Medicine News:Health News:Vitamin C Could Help in Curbing Cancer 2Health News:Race Affects Tobacco Absorption in Children 2
(Date:8/1/2014)... LAWRENCE, Mass. , Aug. 1, 2014  NxStage Medical, ... innovative dialysis products, today announced that Jeffrey H. Burbank ... Financial Officer, will present at the 34 th Annual ... Boston, MA , on Wednesday, August 13 ... event will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
(Date:7/31/2014)... , July 31, 2014  According to data ... Services, the 2015 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... GeneXpert(R) System ... ... today announced the U.S. Food & Drug Administration (FDA) categorized,Cepheid,s ... Clinical Laboratory Improvement Amendments (CLIA).,The new test is designed for ...
... Michael J. Fox,Foundation today announced the availability of ... toward transformative treatments and a cure for,Parkinson,s disease., ... researchers through the,Foundation,s Pipeline Programs, five separate initiatives ... drug development pipeline. This includes,early-stage discovery research, translational ...
Cached Medicine Technology:Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 4Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 2Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 3Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: